Knight Therapeutics (TSE:GUD) Shares Down 0.5% - Should You Sell?

Key Points

• Shares fell 0.5% to C$7.51 on Wednesday with 55,575 shares traded, about 39% below the average session volume.
• Profitability is weak: the company reports a negative net margin (-1.19%), negative PE (-150.20) and negative ROE, despite posting C$0.09 EPS and C$133.2M revenue last quarter and an analyst EPS forecast of ~C$0.10 for the year.
• Liquidity appears solid (current ratio 2.39, quick ratio 1.79), but the firm has a very high debt-to-equity of 10.15, suggesting elevated leverage risk; market cap is C$736.4M and the stock trades above its 50- and 200-day SMAs.

Knight Therapeutics Inc. (TSE:GUD - Get Free Report)'s share price traded down 0.5% during trading on Wednesday . The company traded as low as C$7.49 and last traded at C$7.51. 55,575 shares traded hands during trading, a decline of 39% from the average session volume of 91,436 shares. The stock had previously closed at C$7.55.

Knight Therapeutics Stock Performance

The company has a debt-to-equity ratio of 10.15, a current ratio of 2.39 and a quick ratio of 1.79. The business has a 50-day simple moving average of C$6.99 and a 200 day simple moving average of C$6.34. The firm has a market cap of C$736.40 million, a PE ratio of -150.20, a PEG ratio of -1,013.50 and a beta of -0.21.

Knight Therapeutics (TSE:GUD - Get Free Report) last issued its quarterly earnings results on Thursday, March 19th. The company reported C$0.09 EPS for the quarter. The business had revenue of C$133.20 million during the quarter. Knight Therapeutics had a negative return on equity of 0.70% and a negative net margin of 1.19%. Equities research analysts forecast that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.